Spero Therapeutics (SPRO) Operating Margin (2016 - 2026)

Spero Therapeutics (SPRO) has reported Operating Margin for 11 consecutive years, with 2921.71% the latest figure, recorded in Q1 2026.

• For the quarter ending Q1 2026, Operating Margin fell 267092.0% year-over-year to 2921.71%; the trailing twelve-month figure through Jun 2026 stood at 12.82% (up 13118.0% YoY), and the FY2025 full-year result was 9.45%, up 16236.0% from the prior year.
• Operating Margin declined to 2921.71% in Q1 2026 per SPRO's latest filing, from 76.05% in the prior quarter.
• Across five years, Operating Margin topped out at 76.05% in Q4 2025 and bottomed at 2921.71% in Q1 2026.
• Historically, Operating Margin has averaged 487.31% across 5 years, with a median of 150.88% in 2024.
• The sharpest annual moves came in 2022 and 2026: Operating Margin soared 105690 bps in 2022, then plunged 267092 bps in 2026.
• Over 5 years, Operating Margin stood at 54.64% in 2022, then gained by 26 bps to 68.73% in 2023, then plunged by 310 bps to 144.41% in 2024, then jumped by 153 bps to 76.05% in 2025, then sank by 3942 bps to 2921.71% in 2026.
• According to Business Quant data, Operating Margin over the past three periods registered 2921.71%, 76.05%, and 145.46% for Q1 2026, Q4 2025, and Q3 2025 respectively.